A5011687402- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- Endometriosis Research and Treatment
- PARP inhibition in cancer therapy
- Breast Lesions and Carcinomas
- Cancer survivorship and care
- Chronic Lymphocytic Leukemia Research
- Gynecological conditions and treatments
- Cancer Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Metastasis and carcinoma case studies
- Monoclonal and Polyclonal Antibodies Research
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Minimally Invasive Surgical Techniques
- Organ and Tissue Transplantation Research
University Medical Center Freiburg
2022-2025
University of Freiburg
2023-2024
Klinik für Frauenheilkunde
2024
Saarland University
2023
University of Tübingen
2013-2022
University Hospital of Zurich
2019-2021
University Children's Hospital Tübingen
2016-2020
Universitätsklinikum Tübingen
2015-2019
Olgahospital
2018
University Hospital Heidelberg
2017
The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) a indicator of high-risk disease EC. In the current study, it was our aim determine prognostic significance aberrant L1CAM expression ProMisE subgroups large, single centre, population-based EC cohort.ProMisE (POLE; MMR-D; p53 wt/NSMP;...
Progress has been made in the treatment of metastatic breast cancer recent decades, but very few therapies use patient or tumor-specific characteristics to tailor individualized treatment. More than ten years after publication reference human genome sequence, analysis methods have improved enormously, fostering hope that biomarkers can be used individualize and offer precise based on tumor characteristics. Biomarkers at every level system (genetics, epigenetics, gene expression, micro-RNA,...
Uterus transplantation (UTx) can provide a route to motherhood for women with Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS), congenital disorder characterized by uterovaginal aplasia, but functional ovaries. Based on our four successful living-donor transplantations and two resulting births, this analysis presents parameters relevant standardizing recipient/donor selection, UTx surgery, postoperative treatment, their implementation in routine settings. We descriptively analyzed...
PurposeTreatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients advanced hormone receptor–positive, HER2-negative (HR HER2–) breast cancer (BC). However, real-world data on the implementation of usage, efficacy, toxicity have not yet been reported.MethodsThe PRAEGNANT registry was used to identify HR HER2– BC (n = 1136). The use chemotherapy, ET, everolimus CDK4/6i ET analyzed first-line, second-line, third-line therapy. Progression-free survival (PFS)...
Background: Breast cancer represents the most common malignant disease in women worldwide. As currently systematic palliative treatment only has a limited effect on survival rates, concept of health-related quality life (HRQoL) is gaining more and importance therapy setting metastatic breast cancer. One major patient-reported outcomes (PROs) for measuring HRQoL patients with provided by European Organization Research Treatment Cancer (EORTC). Currently, paper-based surveys still predominate,...
Background: Patient-reported outcomes (PROs) play an increasingly important role as adjunct to clinical outcome parameters in measuring health-related quality of life (HRQoL). In fact, PROs are already the accepted gold standard for collecting data about patients' subjective perception their own state health. Currently, paper-based surveys PRO still predominate; however, knowledge regarding feasibility and barriers electronic-based (ePRO) acceptance remains limited. Objective: The objective...
In recent years, new targeted therapies have been developed to treat patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Some of these not just become the therapy standard but also led significantly longer overall survival rates. The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) therapeutic for first-line therapy. Around 70 - 80% are treated a CDK4/6i. number biomarkers associated progression, clonal selection or...
Patients with first-line metastatic breast cancer (MBC) comprise patients de novo metastases (dnMBC) or recurrent disease after primary (rMBC). This analysis aimed to explore the prognostic value of dnMBC versus rMBC overall and particularly in subgroups according age metastasis site, addition other clinicopathological parameters a first-line, hormone receptor (HR)-positive, HER2-negative (HRpos/HER2neg) population. Within prospective PRAEGNANT MBC registry (NCT02338167), 508 HRpos/HER2neg...
Zusammenfassung Für Patientinnen wie auch Patienten mit hormonrezeptorpositivem (HRpos)/Human epidermal growth factor receptor 2- negativem (HER2neg) Mammakarzinom wurden in den letzten Jahren einige neue, zielgerichtete Therapien eingeführt. Einige dieser Behandlungen konnten sich nicht nur als neuer Therapiestandard etablieren, sondern führten zu einem signifikant verlängerten Gesamtüberleben. Insbesondere die Cyclin-dependent Kinase 4 and 6 Inhibitors (CDK4/6i) haben der ersten...
The aim of the study was to evaluate efficacy high intensity focused ultrasound (HIFU) in treatment symptomatic breast fibroadenomas (FA) after 6 and 12 months.Between December 2013 November 2014, 27 patients with histologically confirmed FA received one application HIFU under local anesthesia (NCT02011919). Follow-up visits occurred months measuring volume clinical symptoms. A reduction more than 65% defined as success. Core needle biopsy (CNB) offered if indistinct residuals were visible...
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns trastuzumab (H), pertuzumab + (PH), lapatinib (L), and emtansine (T-DM1). The PRAEGNANT is a real-time, registry for MBC patients. All lines are documented. analysis utilization anti-HER2 as well sequences. Among 1936 PRAEGNANT, 451 were (23.3%). In set (417...
In BOLERO-2, adding everolimus to exemestane resulted in a twofold increase median progression-free survival (PFS) vs postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) after progression on non-steroidal aromatase inhibitor (NSAI). Here, we report the open-label, single-arm, phase IIIB 4EVER trial (NCT01626222). This evaluated clinical effectiveness of plus HR+, HER2- aBC who had progressed or an...